No Abbott Product

Device Abbott Laboratories
Total Payments
$46,816
Transactions
21
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $46,816 21 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $46,816 21 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device Abbott Laboratories $28,647 0
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Zephir Inhaler Device Abbott Laboratories $16,275 0
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma Abbott Laboratories $1,894 0

Top Doctors Receiving Payments for No Abbott Product

Doctor Specialty Location Total Records
Unknown Orlando, FL $46,816 21

About No Abbott Product

No Abbott Product is a device associated with $46,816 in payments to 0 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.

Payment data is available from 2024 to 2024. In 2024, $46,816 was paid across 21 transactions to 0 doctors.

The most common payment nature for No Abbott Product is "Unspecified" ($46,816, 100.0% of total).

No Abbott Product is associated with 3 research studies, including "Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device" ($28,647).